Bluejay Diagnostics (NASDAQ:BJDX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Bluejay Diagnostics (NASDAQ:BJDX) from a sell rating to a hold rating in a research note issued to investors on Saturday morning.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Bluejay Diagnostics Stock Down 2.9%

NASDAQ BJDX opened at $1.02 on Friday. Bluejay Diagnostics has a 52-week low of $0.83 and a 52-week high of $16.68. The business’s 50-day moving average price is $2.00 and its 200 day moving average price is $2.18. The firm has a market cap of $1.05 million, a P/E ratio of -0.09 and a beta of 0.89.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($1.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3,520.00) by $3,518.88.

Insider Transactions at Bluejay Diagnostics

In other Bluejay Diagnostics news, major shareholder Financial Lp Hrt acquired 64,047 shares of the business’s stock in a transaction on Thursday, July 9th. The stock was purchased at an average price of $1.51 per share, for a total transaction of $96,710.97. Following the completion of the transaction, the insider owned 126,993 shares of the company’s stock, valued at $191,759.43. The trade was a 101.75% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Bluejay Diagnostics

An institutional investor recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics as of its most recent SEC filing. Hedge funds and other institutional investors own 18.47% of the company’s stock.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.